REFERENCES
1. McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017;121:731-48.
2. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:749-70.
3. Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation 2020;141:387-98.
4. Walsh R, Buchan R, Wilk A, et al. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J 2017;38:3461-8.
5. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:1850-8.
6. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the american college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 2020;76:e159-240.
7. Dai J, Li Z, Huang W, et al. RBM20 is a candidate gene for hypertrophic cardiomyopathy. Can J Cardiol 2021;37:1751-9.
8. McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
9. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for illumina sequence data. Bioinformatics 2014;30:2114-20.
10. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010;38:e164.
11. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. Nat Genet 2016;48:1581-6.
12. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet 2016;99:877-85.
13. Rehm HL, Berg JS, Brooks LD, et al. ClinGen-the clinical genome resource. N Engl J Med 2015;372:2235-42.
14. Xiao L, Li C, Sun Y, et al. Clinical significance of variants in the TTN gene in a large cohort of patients with sporadic dilated cardiomyopathy. Front Cardiovasc Med 2021;8:657689.
15. Jiang DS, Yi X, Li R, et al. The histone methyltransferase mixed lineage leukemia (MLL)3 may play a potential role on clinical dilated cardiomyopathy. Mol Med 2017;23:196-203.
16. Ansari KI, Mandal SS. Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J 2010;277:1790-804.
17. Amorim S, Campelo M, Moura B, et al. The role of biomarkers in dilated cardiomyopathy: assessment of clinical severity and reverse remodeling. Rev Port Cardiol 2017;36:709-16.
18. Karaca O, Guler GB, Guler E, et al. Serum carbohydrate antigen 125 levels in nonischemic dilated cardiomyopathy: a useful biomarker for prognosis and functional mitral regurgitation. Congest Heart Fail 2012;18:144-50.
19. Tan L, Li Z, Zhou C, et al. FBN1 mutations largely contribute to sporadic non-syndromic aortic dissection. Hum Mol Genet 2017;26:4814-22.
20. Wang JJ, Yu B, Sun Y, Song X, Wang DW, Li Z. FBN1 Splice-altering mutations in marfan syndrome: a case report and literature review. Genes 2022;13:1842.
21. Landstrom AP, Dobrev D, Wehrens XHT. Calcium signaling and cardiac arrhythmias. Circ Res 2017;120:1969-93.
